贝利尤单抗治疗狼疮肾炎的真实世界深度肾脏缓解研究
单中心回顾性队列纳入51例活检证实的狼疮肾炎患者,其中43例基线未达完全肾脏缓解(CRR),接受贝利尤单抗附加治疗。12和24个月深度临床肾脏缓解(DCRR)达成率分别为38.5%和53.8%,CRR为66.7%和76.9%;8例配对活检显示活动性指数下降而慢性化指数上升。
要点
- 贝利尤单抗附加治疗下DCRR在24个月可达53.8%,高于12个月的38.5%。
- 基线uPCR是唯一与12个月肾脏缓解持续相关的变量。
- 配对活检显示活动性指数下降但慢性化指数上升,样本小需谨慎解读。
核心结论
- 深度肾脏缓解伴随组织学活动性消退,在 growing 比例的患者中可实现,但对长期肾脏保护的影响尚待确定。
研究设计与样本
- 单中心回顾性队列研究,纳入2015至2025年活检证实的狼疮肾炎接受附加贝利尤单抗治疗者,随访至24个月,含配对活检亚组。
主要发现
- 51例患者中43例基线未达CRR并纳入分析,DCRR在12和24个月达成率分别为38.5%和53.8%,CRR分别为66.7%和76.9%。
- 深度缓解累积较慢,DCRR中位时间17.7个月,CRR中位时间7.5个月,第二年仍在增加。
- 基线uPCR是唯一与12个月缓解持续相关的变量。
- 肾脏缓解伴随系统活动度、血清学标志物和糖皮质激素暴露改善:SLEDAI-2K从13降至2,抗dsDNA从205降至54 IU/mL,72%患者激素减量。
- 8例配对活检中活动性指数从5.5降至2(p=0.016),肾小球C3沉积从3+减至1+(p=0.031),慢性化指数上升。
关键数值与推荐
- DCRR定义为uPCR<200 mg/g、无活动性肾小球血尿且肾功能稳定;传统CRR定义为uPCR<500 mg/g且肾功能稳定。
临床怎么用
- 贝利尤单抗附加治疗可考虑用于追求更深肾脏缓解的狼疮肾炎患者,但需监测慢性化指标变化。
局限性
- 单中心回顾性设计,样本量小(配对活检仅8例),无对照组,组织学发现为探索性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Lupus nephritis (LN) often progresses despite therapy, and current complete renal response (CRR) definitions tolerate residual proteinuria deemed suboptimal in other glomerulopathies. Belimumab, the first biologic approved for active LN, may enable deeper remission, but its real-world effectiveness is unknown. METHODS: We retrospectively studied a single-centre cohort of biopsy-proven LN receiving add-on belimumab (2015-2025), with follow-up to 24 months and a paired-biopsy subgroup. We explored a study-specific stringent composite endpoint, deep clinical renal response (DCRR): urine protein-to-creatinine ratio (uPCR) <200 mg/g, absence of active glomerular haematuria and stable renal function, benchmarked against conventional CRR (uPCR <500 mg/g, stable renal function). RESULTS: Of 51 patients, 43 not in CRR at initiation were analysed. DCRR was achieved by 38.5% at 12 and 53.8% at 24 months, versus 66.7% and 76.9% for CRR, in available-case analysis; deep responses accrued gradually (median 17.7 vs 7.5 months), still increasing during the second year. Baseline uPCR was the only variable consistently associated with 12-month response. Renal response occurred alongside improvements in systemic activity, serological markers, and glucocorticoid exposure (SLEDAI-2K 13 to 2; anti-dsDNA 205 to 54 IU/mL and glucocorticoid reduction in 72%). In eight paired biopsies, activity index fell from 5.5 to 2 (p = 0.016) with attenuated glomerular C3 deposition (3+ to 1+, p = 0.031), whereas chronicity indices rose; these findings are exploratory given the small, uncontrolled sample. CONCLUSION: Deep renal response, accompanied by regression of histological activity, appears achievable in a growing proportion of patients. However, its impact on long-term renal protection remains to be established.
引用
- Xipell M, Garbarino MC, Rodríguez-Pintó I, et al. Deep clinical renal response in lupus nephritis treated with belimumab: a real-world cohort study. Rheumatology (Oxford). 2026. PMID: 42900520. doi:10.1093/rheumatology/keag590
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。